BioAtla, Inc.
News
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
Globe Newswire SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...\n more…
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...\n more…
Vanguard Group Inc. Increases Stock Holdings in BioAtla, Inc. (NASDAQ:BCAB)
Ticker Report Vanguard Group Inc. increased its stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) by 0.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional...\n more…
